12/22/21 Health Advisory: Paxlovid granted EUA and Testing before gathering

COVID-19 Updates for Providers

Requested actions


As Omicron cases surge in our region—and communities gather for the holidays—we welcome news of additional tools to combat COVID-19 and reduce the burden on our healthcare systems. We are working with DOH and local healthcare partners to establish equitable access and distribution as these therapeutics become available.

Paxlovid and ritonavir prescribing information is contained in their EUAs:

  • Before prescribing, clinicians should carefully review drug interaction.
  • Paxlovid is provided as 2 pink 150 mg tablets co-packaged with 1 white 100 mg tablet of ritonavir. People already taking ritonavir for another condition should be counseled to not take the white tablet with their dose. These medications should be taken as a single dose at the same time every day.
  • This combination therapy has not been studied during pregnancy or lactation but the EUA does allow for use in this population with proper informed consent.
  • Paxlovid should not be used by people with severe liver and/or renal disease. People with moderate reductions in renal function may require dose modifications.

Paxlovid and ritonavir supplies will be significantly limited initially. We await guidance from DOH on how many doses will be allocated to Washington and where they will be sent.

Additional information

COVID-19 vaccine

COVID-19 testing

COVID-19 therapeutics

HHS allocates monoclonal antibody and oral antiviral supplies to each state. DOH distributes doses to enrolled providers. Providers must enroll in HPoP to manage COVID-19 therapeutics. Email mcm@doh.wa.gov to register for HPoP training, held Tuesdays at 9 a.m.

Find more resources in the COVID-19 monoclonal antibody therapeutics communication toolkit.

COVID-19 prevention patient education

Share the following materials with patients.

Immediately report COVID-19

Contacting the Health Department

Additional resources